OncoMatch/Clinical Trials/NCT03838926
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Is NCT03838926 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Trichostatin A for relapsed or refractory hematologic malignancies.
Treatment: Trichostatin A — The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Cardiac function
Impaired cardiac function or conduction defect [excluded]
Impaired cardiac function or conduction defect
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Vanda Investigational Site · Washington D.C., District of Columbia
- Vanda Investigational Site · Lafayette, Indiana
- Vanda Investigational Site · Hackensack, New Jersey
- Vanda Investigational Site · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify